Equidacent
Bevacizumab biosimilar developed by Centus Biotherapeutics (Fujifilm Kyowa Kirin and AstraZeneca), development code FKB238. Reference product Avastin.
Brands by market: Equidacent (EU, withdrawn) · Commercial partner or holder: Centus Biotherapeutics
FDAnot listed
EMAwithdrawn
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Equidacent
European Medicines Agency and European CommissionWithdrawnBrand
Equidacent
Holder or applicant
Centus Biotherapeutics Europe Limited
Pathway
Centralised (Article 10(4))
Approved
Sep 2020
Application or permission
EMEA/H/C/005181
Withdrawn
date not published
Presentations
see SmPC
Note
Withdrawn by the holder; date not published in the EMA table.
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning bevacizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.